Your browser doesn't support javascript.
loading
The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations.
Bodini, Margherita; Ronchini, Chiara; Giacò, Luciano; Russo, Anna; Melloni, Giorgio E M; Luzi, Lucilla; Sardella, Domenico; Volorio, Sara; Hasan, Syed K; Ottone, Tiziana; Lavorgna, Serena; Lo-Coco, Francesco; Candoni, Anna; Fanin, Renato; Toffoletti, Eleonora; Iacobucci, Ilaria; Martinelli, Giovanni; Cignetti, Alessandro; Tarella, Corrado; Bernard, Loris; Pelicci, Pier Giuseppe; Riva, Laura.
  • Bodini M; Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Milan, Italy;
  • Ronchini C; Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Milan, Italy;
  • Giacò L; Department of Experimental Oncology, European Institute of Oncology, Milan, Italy;
  • Russo A; Department of Experimental Oncology, European Institute of Oncology, Milan, Italy;
  • Melloni GE; Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Milan, Italy;
  • Luzi L; Department of Experimental Oncology, European Institute of Oncology, Milan, Italy; IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy;
  • Sardella D; IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy; Cogentech, Milan, Italy;
  • Volorio S; IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy; Cogentech, Milan, Italy;
  • Hasan SK; Department of Medical Oncology, Advanced Centre for Treatment, Research & Education in Cancer, Navi Mumbai, India; Department of Biomedicine and Prevention, University of "Rome Tor Vergata," Rome, Italy; Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, Rome, Italy;
  • Ottone T; Department of Biomedicine and Prevention, University of "Rome Tor Vergata," Rome, Italy; Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, Rome, Italy;
  • Lavorgna S; Department of Biomedicine and Prevention, University of "Rome Tor Vergata," Rome, Italy; Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, Rome, Italy;
  • Lo-Coco F; Department of Biomedicine and Prevention, University of "Rome Tor Vergata," Rome, Italy; Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, Rome, Italy;
  • Candoni A; Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy;
  • Fanin R; Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy;
  • Toffoletti E; Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy;
  • Iacobucci I; Institute of Hematology "Seràgnoli," Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy;
  • Martinelli G; Institute of Hematology "Seràgnoli," Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy;
  • Cignetti A; University Division of Hematology and Cell Therapy, Mauriziano Hospital and University of Torino, Torino, Italy; and.
  • Tarella C; University Division of Hematology and Cell Therapy, Mauriziano Hospital and University of Torino, Torino, Italy; and.
  • Bernard L; Department of Experimental Oncology, European Institute of Oncology, Milan, Italy; Cogentech, Milan, Italy;
  • Pelicci PG; Department of Experimental Oncology, European Institute of Oncology, Milan, Italy; Dipartimento di Scienze della salute, Università degli Studi di Milano, Milan, Italy.
  • Riva L; Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia, Milan, Italy;
Blood ; 125(4): 600-5, 2015 Jan 22.
Article en En | MEDLINE | ID: mdl-25499761
ABSTRACT
The analyses carried out using 2 different bioinformatics pipelines (SomaticSniper and MuTect) on the same set of genomic data from 133 acute myeloid leukemia (AML) patients, sequenced inside the Cancer Genome Atlas project, gave discrepant results. We subsequently tested these 2 variant-calling pipelines on 20 leukemia samples from our series (19 primary AMLs and 1 secondary AML). By validating many of the predicted somatic variants (variant allele frequencies ranging from 100% to 5%), we observed significantly different calling efficiencies. In particular, despite relatively high specificity, sensitivity was poor in both pipelines resulting in a high rate of false negatives. Our findings raise the possibility that landscapes of AML genomes might be more complex than previously reported and characterized by the presence of hundreds of genes mutated at low variant allele frequency, suggesting that the application of genome sequencing to the clinic requires a careful and critical evaluation. We think that improvements in technology and workflow standardization, through the generation of clear experimental and bioinformatics guidelines, are fundamental to translate the use of next-generation sequencing from research to the clinic and to transform genomic information into better diagnosis and outcomes for the patient.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Genoma Humano / Bases de Datos de Ácidos Nucleicos / Frecuencia de los Genes / Mutación Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Año: 2015 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Genoma Humano / Bases de Datos de Ácidos Nucleicos / Frecuencia de los Genes / Mutación Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Año: 2015 Tipo del documento: Article